PubMed:11780382 JSONTXT

{"project":"FSU-PRGE","denotations":[{"id":"T1","span":{"begin":13,"end":22},"obj":"protein"},{"id":"T2","span":{"begin":60,"end":76},"obj":"protein"},{"id":"T3","span":{"begin":160,"end":169},"obj":"protein"},{"id":"T4","span":{"begin":188,"end":204},"obj":"protein"},{"id":"T5","span":{"begin":236,"end":245},"obj":"protein"},{"id":"T6","span":{"begin":427,"end":443},"obj":"protein"},{"id":"T7","span":{"begin":464,"end":473},"obj":"protein"},{"id":"T8","span":{"begin":660,"end":664},"obj":"protein"},{"id":"T9","span":{"begin":712,"end":721},"obj":"protein"},{"id":"T10","span":{"begin":742,"end":751},"obj":"protein"},{"id":"T11","span":{"begin":801,"end":805},"obj":"protein"},{"id":"T12","span":{"begin":840,"end":849},"obj":"protein"},{"id":"T13","span":{"begin":884,"end":893},"obj":"protein"},{"id":"T14","span":{"begin":956,"end":965},"obj":"protein"},{"id":"T15","span":{"begin":981,"end":990},"obj":"protein"},{"id":"T16","span":{"begin":1025,"end":1034},"obj":"protein"},{"id":"T17","span":{"begin":1102,"end":1106},"obj":"protein"},{"id":"T18","span":{"begin":1246,"end":1255},"obj":"protein"},{"id":"T19","span":{"begin":1315,"end":1324},"obj":"protein"},{"id":"T20","span":{"begin":1378,"end":1394},"obj":"protein"},{"id":"T21","span":{"begin":1444,"end":1453},"obj":"protein"},{"id":"T22","span":{"begin":1522,"end":1531},"obj":"protein"},{"id":"T23","span":{"begin":1581,"end":1597},"obj":"protein"}],"text":"Th1/Th2 type cytokines in hepatitis B patients treated with interferon-alpha.\nOBJECTIVE: To investigate the relationship between the expression of Th1/Th2 type cytokines and the effect of interferon-alpha therapy.\nMETHODS: Th1/Th2 type cytokines were assayed by enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) on 23 patients with chronic hepatitis B who were treated with interferon-alpha.\nRESULTS: Levels of IFN-gamma in the supernatant of peripheral blood mononuclear cells (PBMC) cultures from the patients with hepatitis B were slightly lower than those of controls (P = 0.07). However, the levels of IL-4 were higher than those of controls (P = 0.01). Cytokines measurements during IFN-alpha treatment showed a trend to decreasing levels of IL-4 at 4, 12, and 24 weeks. Levels of IFN-gamma were slightly increased following IFN-alpha treatment (P = 0.09). In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.\nCONCLUSION: The expression of Th2 type cytokines is predominant in patients with chronic hepatitis B. Interferon-alpha therapy can modulate the balance of Th1/Th2 type cytokines, and this is related to its clinical effect. Levels of Th1/Th2 type cytokines could be a predictor of clinical response during Interferon-alpha treatment."}

{"project":"AIMed","denotations":[{"id":"T1","span":{"begin":60,"end":76},"obj":"protein"},{"id":"T2","span":{"begin":188,"end":204},"obj":"protein"},{"id":"T3","span":{"begin":427,"end":443},"obj":"protein"},{"id":"T4","span":{"begin":464,"end":473},"obj":"protein"},{"id":"T5","span":{"begin":660,"end":664},"obj":"protein"},{"id":"T6","span":{"begin":742,"end":751},"obj":"protein"},{"id":"T7","span":{"begin":801,"end":805},"obj":"protein"},{"id":"T8","span":{"begin":840,"end":849},"obj":"protein"},{"id":"T9","span":{"begin":884,"end":893},"obj":"protein"},{"id":"T10","span":{"begin":956,"end":965},"obj":"protein"},{"id":"T11","span":{"begin":981,"end":990},"obj":"protein"},{"id":"T12","span":{"begin":1025,"end":1034},"obj":"protein"},{"id":"T13","span":{"begin":1102,"end":1106},"obj":"protein"},{"id":"T14","span":{"begin":1378,"end":1394},"obj":"protein"},{"id":"T15","span":{"begin":1581,"end":1597},"obj":"protein"}],"text":"Th1/Th2 type cytokines in hepatitis B patients treated with interferon-alpha.\nOBJECTIVE: To investigate the relationship between the expression of Th1/Th2 type cytokines and the effect of interferon-alpha therapy.\nMETHODS: Th1/Th2 type cytokines were assayed by enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) on 23 patients with chronic hepatitis B who were treated with interferon-alpha.\nRESULTS: Levels of IFN-gamma in the supernatant of peripheral blood mononuclear cells (PBMC) cultures from the patients with hepatitis B were slightly lower than those of controls (P = 0.07). However, the levels of IL-4 were higher than those of controls (P = 0.01). Cytokines measurements during IFN-alpha treatment showed a trend to decreasing levels of IL-4 at 4, 12, and 24 weeks. Levels of IFN-gamma were slightly increased following IFN-alpha treatment (P = 0.09). In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.\nCONCLUSION: The expression of Th2 type cytokines is predominant in patients with chronic hepatitis B. Interferon-alpha therapy can modulate the balance of Th1/Th2 type cytokines, and this is related to its clinical effect. Levels of Th1/Th2 type cytokines could be a predictor of clinical response during Interferon-alpha treatment."}